The observed association of CHRNA2 unerexpression with CUD, also implies that the alpha-2 subunit can be a potential drug target in the treatment of CUD, by the use of an agonist selective for alpha-2 subunit containing nAChRs. The impact of some compounds with an agonistic effect on the alpha-2 subunit containing nAChRs, like NS928340, ABT-41841 and TC-173442, have already been studied primarily due to their potential impact on memory and cognitive processese.g. 40,42.
